Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior

Cost: No fee

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, social workers, clinical administrators and healthcare teams.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, SW CE credit, and Interprofessional Continuing Education (IPCE) credit.

Webinar Description: Have you considered prescribing Medications for Opioid Use Disorder (MOUD) to treat your patients with opioid use disorder (OUD)? Have you wondered what is required to prescribe buprenorphine or other pharmacotherapies? If you answered yes to either or both of these questions, this PCSS Exchange session could provide you with the critical information and steps in determining the readiness of your site and clinical leadership. Initiating MOUD into your setting requires that you understand how pharmacotherapies work, including buprenorphine and its various formulations. Programs must think through the business case for service expansion and strategize how to best engage key staff.

Educational Objectives:

• Summarize the financial and clinical considerations of incorporating MOUD into their practice
• Identify the three FDA-approved medications to treat opioid use disorder and describe the specific formulations of buprenorphine
• Identify resources targeted to non-prescribing members of healthcare teams (e.g., counselors, social workers, clinic administrators, etc.) and resources for prescribers (PCSS and others) to guide implementation of MOUD

Continuing education information:

In support of improving patient care, this activity has been planned and implemented by Addiction Technology Transfer Center Network and American Academy of Addiction Psychiatry. AAAP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE) Designation Statement:

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 Nursing Contact Hours.

PA Designation Statement

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Social Work Designation Statement

As a Jointly Accredited Organization, American Academy of Addiction Psychiatry (AAAP) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. AAAP maintains responsibility for this course. Social workers completing this course receive 1 continuing education credit.